KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Other Non-Current Liabilities (2019 - 2025)

Castle Biosciences' Other Non-Current Liabilities history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, changed N/A, while the annual FY2025 figure was $1.5 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.5 million at Castle Biosciences, roughly flat from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.3 million in Q4 2021 and bottomed at $3000.0 in Q3 2021.
  • The 5-year median for Other Non-Current Liabilities is $95000.0 (2022), against an average of $1.9 million.
  • The largest YoY upside for Other Non-Current Liabilities was 59833.33% in 2022 against a maximum downside of 99.51% in 2022.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $18.3 million in 2021, then plummeted by 99.51% to $90000.0 in 2022, then plummeted by 72.22% to $25000.0 in 2023, then tumbled by 36.0% to $16000.0 in 2024, then surged by 9275.0% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Other Non-Current Liabilities are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).